Anti-CD5 monoclonal antibody OX19

Drug Profile

Anti-CD5 monoclonal antibody OX19

Alternative Names: Monoclonal antibody OX19; OX19

Latest Information Update: 06 Aug 1998

Price : $50

At a glance

  • Originator Takeda
  • Class Monoclonal antibodies
  • Mechanism of Action CD5 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 06 Aug 1998 No-Development-Reported for Transplant rejection in Japan (Unknown route)
  • 19 Jul 1996 Monoclonal antibody OX19 is now called Anti-CD5 monoclonal antibody OX19
  • 08 Sep 1995 Preclinical development for Transplant rejection in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top